PEDF inhibits pancreatic tumorigenesis by attenuating the fibroinflammatory reaction

Oncotarget

Volumn 7, Issue 19, 2016, Pages 28218-28234

  Principe, Daniel R ^a   DeCant, Brian ^b   Diaz, Andrew M ^b   Mangan, Riley J ^b   Hwang, Rosa ^c   Lowy, Andrew ^d   Shetuni, Brandon B ^e   Sreekumar, Bharath K ^f   Chung, Chuhan ^f   Bentrem, David J ^g   Munshi, Hidayatullah G ^g   Jung, Barbara ^b   Grippo, Paul J ^b   Bishehsari, Faraz ^h  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e CENTRAL DUPAGE HOSPITAL   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fibrosis; Inflammation; KRAS; Pancreatic cancer; PEDF

Indexed keywords

CERULETIDE; COLLAGEN TYPE 1; K RAS PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GENETIC TRANSFECTION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STELLATE CELL; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DISEASE EXACERBATION; KNOCKOUT MOUSE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; DISEASE PROGRESSION; EYE PROTEINS; FIBROSIS; HUMANS; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE GROWTH FACTORS; PANCREATIC NEOPLASMS; SERPINS; TUMOR MICROENVIRONMENT;

EID: 84968912202     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8587     Document Type: Article

References (78)

1. Coussens LM and Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
2. Jarnicki A, Putoczki T and Ernst M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell division. 2010; 5:14.
3. Lin WW and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. The Journal of clinical investigation. 2007; 117:1175-1183.
4. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
5. Cai SW, Yang SZ, Gao J, Pan K, Chen JY, Wang YL, Wei LX and Dong JH. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery. 2011; 149:576-584.
6. Evans A and Costello E. The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Front Physiol. 2012; 3:270.
7. Farrow B and Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002; 10:153-169.
8. Bansal P and Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 1995; 109:247-251.
9. Carriere C, Young AL, Gunn JR, Longnecker DS and Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochemical and biophysical research communications. 2009; 382:561-565.
10. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A and Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993; 328:1433-1437.
11. Ancrile BB, O'Hayer KM and Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Molecular interventions. 2008; 8:22-27.
12. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ and Vonderheide RH. Tumor-derived granulocytemacrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer cell. 2012; 21:822-835.
13. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C and Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. The Journal of experimental medicine. 2011; 208:469-478.
14. Foley K, Kim V, Jaffee E and Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer letters. 2015.
15. Kotteas E, Saif MW and Syrigos K. Immunotherapy for pancreatic cancer. Journal of cancer research and clinical oncology. 2016.
16. Mielgo A and Schmid MC. Impact of tumour associated macrophages in pancreatic cancer. BMB reports. 2013; 46:131-138.
17. Yamasaki A, Kameda C, Xu R, Tanaka H, Tasaka T, Chikazawa N, Suzuki H, Morisaki T, Kubo M, Onishi H, Tanaka M and Katano M. Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer Immunol Immunother. 2010; 59:675-686.
18. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM and Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 2011; 60:861-868.
19. Shields MA, Dangi-Garimella S, Redig AJ and Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J. 2012; 441:541-552.
20. Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG, Ramsay AG and Kocher HM. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013; 145:1121-1132.
21. Omary MB, Lugea A, Lowe AW and Pandol SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. The Journal of clinical investigation. 2007; 117:50-59.
22. Ottaviano AJ, Sun L, Ananthanarayanan V and Munshi HG. Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer research. 2006; 66:7032-7040.
23. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ. TGF-beta: Duality of Function Between Tumor Prevention and Carcinogenesis. J Natl Cancer Inst. 2014; 106:djt369.
24. Shields MA, Ebine K, Sahai V, Kumar K, Siddiqui K, Hwang RF, Grippo PJ and Munshi HG. Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res. 2013; 11:1078-1087.
25. Krantz SB, Shields MA, Dangi-Garimella S, Cheon EC, Barron MR, Hwang RF, Rao MS, Grippo PJ, Bentrem DJ and Munshi HG. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-beta signaling. Mol Cancer Res. 2011; 9:1294-1304.
26. Yamagishi S and Matsui T. Pigment epithelium-derived factor (PEDF) and cardiometabolic disorders. Current pharmaceutical design. 2014; 20:2377-2386.
27. Zhang SX, Wang JJ, Gao G, Shao C, Mott R and Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB journal. 2006; 20:323-325.
28. Becerra SP and Notario V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer. 2013; 13:258-271.
29. Chen J, Ye L, Zhang L and Jiang WG. The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol. 2009; 35:159-166.
30. Hong H, Zhou T, Fang S, Jia M, Xu Z, Dai Z, Li C, Li S, Li L, Zhang T, Qi W, Bardeesi AS, Yang Z, Cai W, Yang X and Gao G. Pigment epithelium-derived factor (PEDF) inhibits breast cancer metastasis by down-regulating fibronectin. Breast Cancer Res Treat. 2014; 148:61-72.
31. Filleur S, Nelius T, de Riese W and Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. Journal of cellular biochemistry. 2009; 106:769-775.
32. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G and Zechner R. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science. 2006; 312:734-737.
33. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J and Crawford SE. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med. 2003; 9:774-780.
34. Huang Q, Wang S, Sorenson CM and Sheibani N. PEDFdeficient mice exhibit an enhanced rate of retinal vascular expansion and are more sensitive to hyperoxia-mediated vessel obliteration. Exp Eye Res. 2008; 87:226-241.
35. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A and Li Z. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. The Journal of biological chemistry. 2009; 284:10480-10490.
36. Notari L, Arakaki N, Mueller D, Meier S, Amaral J and Becerra SP. Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase. The FEBS journal. 2010; 277:2192-2205.
37. Notari L, Baladron V, Aroca-Aguilar JD, Balko N, Heredia R, Meyer C, Notario PM, Saravanamuthu S, Nueda ML, Sanchez-Sanchez F, Escribano J, Laborda J and Becerra SP. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. The Journal of biological chemistry. 2006; 281:38022-38037.
38. Samkharadze T, Erkan M, Reiser-Erkan C, Demir IE, Kong B, Ceyhan GO, Michalski CW, Esposito I, Friess H and Kleeff J. Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am J Gastroenterol. 2011; 106:968-980.
39. Schmitz JC, Protiva P, Gattu AK, Utsumi T, Iwakiri Y, Neto AG, Quinn M, Cornwell ML, Fitchev P, Lugea A, Crawford SE and Chung C. Pigment epitheliumderived factor regulates early pancreatic fibrotic responses and suppresses the profibrotic cytokine thrombospondin-1. The American journal of pathology. 2011; 179:2990-2999.
40. Hase R, Miyamoto M, Uehara H, Kadoya M, Ebihara Y, Murakami Y, Takahashi R, Mega S, Li L, Shichinohe T, Kawarada Y and Kondo S. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clinical cancer research. 2005; 11:8737-8744.
41. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Hase R, Takahashi R, Mega S, Shichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S and Katoh H. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer research. 2004; 64:3533-3537.
42. Grippo PJ, Fitchev PS, Bentrem DJ, Melstrom LG, Dangi-Garimella S, Krantz SB, Heiferman MJ, Chung C, Adrian K, Cornwell ML, Flesche JB, Rao SM, Talamonti MS, Munshi HG and Crawford SE. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012; 61:1454-1464.
43. Bartholin L. (2012). Pancreatic cancer and the tumor microenvironment: Mesenchyme's role in pancreatic carcinogenesis. In: Grippo PJ and Munshi HG, eds. Pancreatic Cancer and Tumor Microenvironment. (Trivandrum (India).
44. Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB and Rabinowitz JD. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer research. 2015; 75:544-553.
45. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324:1457-1461.
46. Chilosi M, Mombello A, Montagna L, Benedetti A, Lestani M, Semenzato G and Menestrina F. Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections. J Histochem Cytochem. 1990; 38:1669-1675.
47. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA and Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004; 239:788-797; discussion 797-789.
48. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S and Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer cell. 2005; 7:469-483.
49. Waugh DJ and Wilson C. The interleukin-8 pathway in cancer. Clinical cancer research. 2008; 14:6735-6741.
50. Phillips P. (2012). Pancreatic stellate cells and fibrosis. In: Grippo PJ and Munshi HG, eds. Pancreatic Cancer and Tumor Microenvironment. (Trivandrum (India)).
51. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N and Tuveson DA. The pancreas cancer microenvironment. Clinical cancer research. 2012; 18:4266-4276.
52. Cohen R, Neuzillet C, Tijeras-Raballand A, Faivre S, de Gramont A and Raymond E. Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget. 2015; 6:16832-16847. doi: 10.18632/oncotarget.4160.
53. Cai J, Jiang WG, Grant MB and Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. The Journal of biological chemistry. 2006; 281:3604-3613.
54. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ and Vierra M. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000; 48:919-922.
55. Jan R, Huang M and Lewis-Wambi J. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer. Breast Cancer Res. 2012; 14:R146.
56. Cheung LW, Au SC, Cheung AN, Ngan HY, Tombran-Tink J, Auersperg N and Wong AS. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology. 2006; 147:4179-4191.
57. Matsui T, Nishino Y, Ojima A, Maeda S, Tahara N and Yamagishi S. Pigment epithelium-derived factor improves metabolic derangements and ameliorates dysregulation of adipocytokines in obese type 2 diabetic rats. The American journal of pathology. 2014; 184:1094-1103.
58. Gattu AK, Birkenfeld AL, Iwakiri Y, Jay S, Saltzman M, Doll J, Protiva P, Samuel VT, Crawford SE and Chung C. Pigment epithelium-derived factor (PEDF) suppresses IL-1beta-mediated c-Jun N-terminal kinase (JNK) activation to improve hepatocyte insulin signaling. Endocrinology. 2014; 155:1373-1385.
59. Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ and Tombran-Tink J. Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol Med. 2012; 18:1387-1401.
60. Park K, Jin J, Hu Y, Zhou K and Ma JX. Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. The American journal of pathology. 2011; 178:688-698.
61. Crowe S, Wu LE, Economou C, Turpin SM, Matzaris M, Hoehn KL, Hevener AL, James DE, Duh EJ and Watt MJ. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab. 2009; 10:40-47.
62. Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikstrom P and Bergh A. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia. 2010; 12:336-345.
63. Garcea G, Dennison AR, Steward WP and Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology. 2005; 5:514-529.
64. Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese W and Filleur S. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFkappaB and PPARgamma. Cytokine. 2011; 55:202-210.
65. Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P and Liu L. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014; 4:5911.
66. Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen P and Zhu MH. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol. 2012; 18:1123-1129.
67. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N and Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol. 2003; 22:765-771.
68. Wynn TA. Cellular and molecular mechanisms of fibrosis. The Journal of pathology. 2008; 214:199-210.
69. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer cell. 2014; 25:719-734.
70. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer cell. 2014; 25:735-747.
71. Apte MV, Haber PS, Darby SJ, Rodgers SC, McCaughan GW, Korsten MA, Pirola RC and Wilson JS. Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut. 1999; 44:534-541.
72. Ho TC, Chen SL, Shih SC, Wu JY, Han WH, Cheng HC, Yang SL and Tsao YP. Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells. The American journal of pathology. 2010; 177:1798-1811.
73. Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J and Fernandez M. Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats. Gut. 2015; 64:657-666.
74. Wang JJ, Zhang SX, Lu K, Chen Y, Mott R, Sato S and Ma JX. Decreased expression of pigment epitheliumderived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes. 2005; 54:243-250.
75. Wang JJ, Zhang SX, Mott R, Knapp RR, Cao W, Lau K and Ma JX. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes. 2006; 55:1678-1685.
76. Grippo PJ, Nowlin PS, Demeure MJ, Longnecker DS and Sandgren EP. Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer research. 2003; 63:2016-2019.
77. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer cell. 2003; 4:437-450.
78. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N and Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008; 111:5457-5466.